Blackstone’s Inhibikase Therapeutics IKT Stock Holding History
Bought
Maintained
Sold
Other funds holding IKT
SL
Blackstone's IKT Position: Q2 2026 in Review
Blackstone held its Inhibikase Therapeutics (IKT) position steady in Q2 2026 at 5,938,276 shares worth $12.1M. The position accounts for 0.03% of the portfolio, ranked #91.
Blackstone first reported a position in IKT in Q4 2024 and has held it in 7 quarters since. The position peaked at $12.2M in Q4 2025. 105 funds tracked by Wall St. Rank hold IKT as of Q2 2026.
- Blackstone held 5,938,276 shares of Inhibikase Therapeutics worth $12.1M as of Q2 2026.
- Blackstone left its Inhibikase Therapeutics share count unchanged in Q2 2026.
- Inhibikase Therapeutics made up 0.03% of Blackstone's portfolio in Q2 2026, its #91 holding.
- Blackstone first reported a position in Inhibikase Therapeutics in Q4 2024 and has held it in 7 quarters since.
- Blackstone's Inhibikase Therapeutics position peaked at $12.2M in Q4 2025.
- 105 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.
Based on Blackstone's 13F filing for Q2 2026, filed 14 Aug 2026.